Letrozole Bluefish

Letrozole, the active ingredient in Letrozole Bluefish, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat estrogen‑dependent breast cancer in postmenopausal patients. GNH USA supplies Letrozole Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole acts on estrogen‑dependent pathways in breast cancer, providing therapeutic benefit in several clinical settings.

Postmenopausal breast cancer: reduces estrogen‑driven tumor growth. Adjuvant therapy for early‑stage hormone‑receptor‑positive breast cancer: lowers recurrence risk. Metastatic breast cancer: helps control disease progression.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint and muscle pain: aching discomfort in limbs. - Nausea: mild to moderate upset stomach. - Fatigue: reduced energy and increased tiredness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fractures: increased risk of osteoporosis‑related breaks. - Deep vein thrombosis or pulmonary embolism: swelling, pain, or shortness of breath. - Anaphylactic reaction: hives, swelling, airway compromise. - QT interval prolongation: cardiac rhythm disturbances.

Letrozole requires careful patient assessment and monitoring before and during therapy.

Pregnancy: contraindicated (Category X) – avoid use in pregnant women. Menopause status: only for postmenopausal patients. Bone health: monitor for osteoporosis, consider calcium/vitamin D supplementation. Drug interactions: review concomitant medications for CYP2A6 inhibitors or inducers. Liver function: assess hepatic impairment before initiating therapy. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Letrozole can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors: may increase letrozole plasma levels. - Tamoxifen: antagonistic effect on estrogen suppression. - Estrogen replacement therapy: reduces letrozole effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: may alter INR and bleeding risk. - CYP3A4 inducers (e.g., rifampicin): may reduce letrozole exposure. - Selective serotonin reuptake inhibitors: potential pharmacodynamic interactions.